The Role of IgE and IgG Antibodies in Allergic Reactions: Cellular Mechanisms and Biological Implications

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 144

Special Issue Editors


E-Mail Website
Guest Editor
Department of Immunology, University Clinic for Rheumatology and Immunology, University of Bern, Bern, Switzerland
Interests: allergy; immunotherapy; IgE; CD23; virus-like particles
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Immunology, University Clinic for Rheumatology and Immunology, University of Bern, Bern, Switzerland
Interests: allergy; autoimmunity; CD23; immunotherapy; IgE
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The central role of IgE in allergic diseases has been extensively researched, placing IgE antibodies and their functions at the forefront of therapeutic efforts against allergies. IgE antibodies play a crucial role in initiating and perpetuating allergic inflammation by binding to FcεRI receptors on effector cells. This interaction triggers effector cell activation, leading to the release of potent inflammatory mediators.

In recent years, it has become clear that IgG is an essential regulator of allergic responses. On the one hand, allergen-specific IgG antibodies can induce hypersensitivity reactions by activating Fcg receptors. On the other hand, most clinical and experimental data have identified IgG as a negative regulator of IgE-dependent allergies. Both natural allergen-specific IgG and immunotherapy-induced IgG are capable of suppressing allergies either as blocking or inhibitory antibodies. Other research has shed light on the presence of endogenous anti-IgE IgG autoantibodies which can reduce IgE levels, prevent FcεRI sensitization, and therefore suppress allergy. In addition, recent findings have highlighted the role of glycans in the induction of anti-IgE antibodies, revealing a complex dynamic between glycans, IgE, and IgG in allergic diseases.

This Special Issue aims to provide an overview of the latest progress in understanding the role of IgE and IgG in allergic diseases, covering both cellular mechanisms and biological implications.

Prof. Dr. Monique Vogel
Dr. Paul Engeroff
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • IgE
  • IgG
  • allergy
  • inflammation
  • glycosylation
  • immunotherapy
  • autoantibodies
  • Fc receptors
  • soluble receptors

Published Papers

This special issue is now open for submission.
Back to TopTop